Please use this identifier to cite or link to this item: https://doi.org/10.1097/FPC.0b013e328340bc5a
Title: CYP2C19 variation and citalopram response
Authors: Mrazek, D.A.
Biernacka, J.M.
O'Kane, D.J.
Black, J.L.
Cunningham, J.M.
Drews, M.S.
Snyder, K.A.
Stevens, S.R.
Rush, A.J. 
Weinshilboum, R.M.
Keywords: citalopram
cytochrome P450 2C19
cytochrome P450 2D6
pharmacogenomics
remission
tolerance
Issue Date: Jan-2011
Citation: Mrazek, D.A., Biernacka, J.M., O'Kane, D.J., Black, J.L., Cunningham, J.M., Drews, M.S., Snyder, K.A., Stevens, S.R., Rush, A.J., Weinshilboum, R.M. (2011-01). CYP2C19 variation and citalopram response. Pharmacogenetics and Genomics 21 (1) : 1-9. ScholarBank@NUS Repository. https://doi.org/10.1097/FPC.0b013e328340bc5a
Abstract: Objective: Variations in cytochrome P450 (CYP) genes have been shown to be associated with both accelerated and delayed pharmacokinetic clearance of many psychotropic medications. Citalopram is metabolized by three CYP enzymes. CYP2C19 and CYP3A4 play a primary role in citalopram metabolism, whereas CYP2D6 plays a secondary role. METHODS: The Sequenced Treatment Alternatives to Relieve Depression sample was used to examine the relationship between variations in the CYP2C19 and CYP2D6 genes and remission of depressive symptoms and tolerance to treatment with citalopram. The primary analyses were of the White non-Hispanic patients adherent to the study protocol (n=1074). RESULTS: Generally, patients who had CYP2C19 genotypes associated with decreased metabolism were less likely to tolerate citalopram than those with increased metabolism, although this difference was not statistically significant (P=0.06). However, patients with the inactive 2C19*2 allele had significantly lower odds of tolerance (P=0.02). Patients with the poor metabolism CYP2C19 genotype-based category who were classified as citalopram tolerant were more likely to experience remission (P=0.03). No relationship between CYP2D6 genotype-based categories and either remission or tolerance was identified, although exploratory analyses identified a potential interaction between CYP2C19 and CYP2D6 effects. CONCLUSION: Despite several limitations including the lack of serum drug levels, this study showed that variations in CYP2C19 were associated with tolerance and remission in a large sample of White non-Hispanic patients treated with citalopram. © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins.
Source Title: Pharmacogenetics and Genomics
URI: http://scholarbank.nus.edu.sg/handle/10635/110695
ISSN: 17446872
DOI: 10.1097/FPC.0b013e328340bc5a
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

66
checked on May 20, 2018

WEB OF SCIENCETM
Citations

56
checked on Apr 16, 2018

Page view(s)

48
checked on May 25, 2018

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.